Car-T细胞疗法-话题@MedSci

#Car-T细胞疗法#

56篇内容 | 3039人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1291566, encodeId=96bb1291566a8, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, objectType=article, longId=197391, objectId=8b4a19e3919e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4a19e3919e, replyNumber=0, likeNumber=95, createdTime=2020-07-13, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4a19e3919e, moduleTitle=**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4a19e3919e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291565, encodeId=4e731291565fd, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, objectType=article, longId=195728, objectId=ce9d195e287e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce9d195e287e, replyNumber=0, likeNumber=131, createdTime=2020-06-13, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce9d195e287e, moduleTitle=CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce9d195e287e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291564, encodeId=695a129156425, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, objectType=article, longId=187730, objectId=1d2918e73091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d2918e73091, replyNumber=0, likeNumber=68, createdTime=2020-02-10, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d2918e73091, moduleTitle=Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d2918e73091)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291563, encodeId=50f21291563f0, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, objectType=article, longId=187285, objectId=d73e18e28514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d73e18e28514, replyNumber=0, likeNumber=101, createdTime=2020-02-04, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d73e18e28514, moduleTitle=欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d73e18e28514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291562, encodeId=51141291562cf, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=101, createdTime=2020-02-03, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291561, encodeId=98f51291561be, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, objectType=article, longId=186372, objectId=76531863e2f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76531863e2f1, replyNumber=0, likeNumber=79, createdTime=2020-01-18, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76531863e2f1, moduleTitle=Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76531863e2f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291560, encodeId=efd3129156080, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, objectType=article, longId=184956, objectId=2ccf1849567a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccf1849567a, replyNumber=0, likeNumber=75, createdTime=2019-12-21, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccf1849567a, moduleTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ccf1849567a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291559, encodeId=74bb1291559eb, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=74, createdTime=2019-12-19, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291558, encodeId=5f091291558aa, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, objectType=article, longId=184849, objectId=fa79184849b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa79184849b1, replyNumber=0, likeNumber=66, createdTime=2019-12-18, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa79184849b1, moduleTitle=CAR-T细胞疗法在美国血液学会ASH上大放异彩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa79184849b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291557, encodeId=8ac8129155ec9, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, objectType=article, longId=184844, objectId=f4f518484488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4f518484488, replyNumber=0, likeNumber=81, createdTime=2019-12-18, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4f518484488, moduleTitle=Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4f518484488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291556, encodeId=b29012915566b, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=61, createdTime=2019-12-09, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291555, encodeId=5551129155560, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, objectType=article, longId=182512, objectId=6d2018251202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2018251202, replyNumber=0, likeNumber=0, createdTime=2019-11-08, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2018251202, moduleTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2018251202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291554, encodeId=f6d51291554c1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号, objectType=article, longId=182335, objectId=990d182335ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=990d182335ef, replyNumber=0, likeNumber=77, createdTime=2019-11-05, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=990d182335ef, moduleTitle=科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=990d182335ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291553, encodeId=bce912915533a, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, objectType=article, longId=179626, objectId=eba11e962686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba11e962686, replyNumber=0, likeNumber=58, createdTime=2019-09-19, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba11e962686, moduleTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba11e962686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291552, encodeId=081212915524b, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, objectType=article, longId=178782, objectId=c6a71e8782a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6a71e8782a5, replyNumber=0, likeNumber=84, createdTime=2019-09-05, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6a71e8782a5, moduleTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6a71e8782a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291551, encodeId=989c12915515b, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, objectType=article, longId=165949, objectId=e85d1659491a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85d1659491a, replyNumber=0, likeNumber=61, createdTime=2019-05-14, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85d1659491a, moduleTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85d1659491a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291550, encodeId=a1ee1291550fa, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, objectType=article, longId=165942, objectId=8c7e165942ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e165942ca, replyNumber=0, likeNumber=130, createdTime=2019-05-14, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e165942ca, moduleTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7e165942ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291549, encodeId=9358129154912, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, objectType=article, longId=164173, objectId=17f41641e3ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f41641e3ff, replyNumber=0, likeNumber=0, createdTime=2019-04-14, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f41641e3ff, moduleTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f41641e3ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291548, encodeId=ba561291548e1, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, objectType=article, longId=163641, objectId=23b816364145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b816364145, replyNumber=0, likeNumber=67, createdTime=2019-04-06, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b816364145, moduleTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b816364145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291547, encodeId=4e74129154edb, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, objectType=article, longId=162211, objectId=77bb16221122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77bb16221122, replyNumber=0, likeNumber=87, createdTime=2019-03-14, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77bb16221122, moduleTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77bb16221122)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Car-T细胞疗法

2020-05-29

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

2020-07-13

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法和双特异性抗体再发力：罗氏与信达生物签署20亿美元合作协议

2020-06-13

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Nature Communication：CAR-T细胞疗法后复发怎么办？新型CAR-T疗法或提供帮助

2020-02-10

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19，用于治疗套细胞淋巴瘤

2020-02-04

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Cellectis的同种异体CAR-T细胞疗法（UCART）开始用于治疗复发/难治性急性髓细胞白血病患者

2020-01-18

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

2019-12-21

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2019-12-19

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法在美国血液学会ASH上大放异彩

2019-12-18

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Kite向FDA提交第二种CAR-T细胞疗法的申请，以治疗套细胞淋巴瘤

2019-12-18

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2019-12-09

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定

2019-11-08

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

科济生物CAR-T细胞疗法治疗复发或难治性多发性骨髓瘤，被FDA授予再生医学先进疗法称号

2019-11-05

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND

2019-09-19

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定

2019-09-05

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据

2019-05-14

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

2019-05-14

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法公司Autolus计划后续融资1亿美元

2019-04-14

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Autolus的下一代CAR-T细胞疗法更加安全有效

2019-04-06

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房

2019-03-14

科室
- - 订阅+
  - 更多科室
工具
服务